oligoDOM® is a breakthrough cost-effective technology developed
- Internally, at Osivax, on three indications: Flu, Immuno-oncology and a confidential one with a Big Pharma partner
- In collaboration with public partners in two infectious diseases: Malaria (Jenner Institute, UK) and HPV (DKFZ, Germany)
